Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunshine Biopharma has entered into a contract with Beta Pharma Canada to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug.
Subscribe to our email newsletter
Adva-27a is an anti-cancer compound which has proven effective at killing multidrug resistant breast cancer cells (MCF-7/MDR) and small-cell lung cancer cells (H69AR).
Sunshine president and CEO Steve Slilaty said the company is working with Beta Pharma Canada which has good in-house synthesis capability and can amass additional resources through its corporate affiliations.
"We anticipate delivery of the new batch of Adva-27a together with the synthesis parameters by the end of the month," Slilaty added.
Beta Pharma Canada, an affiliate of Beta Pharma, is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds.